{"prompt": "['Date and version No: FUTUREGB_Protocol_V6.0_19Jan2022.docr', '8.1.', 'Study Participants', '26', '8.2.', 'Inclusion Criteria', '26', '8.3.', 'Exclusion Criteria', '27', '9.', 'PROXY INCLUSION (Stage 2 only)', '27', '9.1.', 'Inclusion Criteria', '27', '10.', 'PROTOCOL PROCEDURES', '28', '10.1. Stage 1: non-randomised multicentre learning and evaluation Stage (IDEAL Stage IIB study)', '28', '10.1.1. Pre-Stage 1 Stage Webinar or Symposium', '28', '10.1.2.', 'IDEAL IIB Study (Quality assurance, mentoring and trial centres learning)', '28', '10.1.3.', 'Pre-RCT Data workflow review', '29', '10.2.', 'Recruitment', '29', '10.2.1.', 'Participants', '29', '10.2.2.', 'Sites', '30', '10.3. Screening and Eligibility Assessment', '30', '10.4. Informed Consent - Participant', '30', '10.4.1.', 'Informed Consent - Proxy (Stage 2 only)', '31', '10.5. Randomisation', '31', '10.6.', 'Blinding and code-breaking', '32', '10.7. Description of study intervention(s), comparators and study procedures (clinical)', '32', '10.7.1.', 'Description of study intervention(s)', '32', '10.7.2.', 'Description of comparator(s)', '33', '10.7.3.', 'Description of study procedure(s) - Stage 1', '33', '10.7.4.', 'Description of study procedure(s) - Stage 2', '33', '10.8. Imaging Schedule for both Stage 1 and 2', '36', '10.9.', 'Sample Handling', '36', '10.10. Early Discontinuation/Withdrawal of Participants', '37', '10.10.1. Stage 1', '37', '10.10.2. Stage 2', '37', 'Clinical Research Protocol Template version 14.0', 'Page 4 of 65', 'C Copyright: The University of Oxford and Oxford University Hospitals NHS Foundation Trust 2018', 'CONFIDENTIAL']['Date and version No: FUTUREGB_Protocol_V6.0_19Jan2022.doc:', '10.11. Definition of End of Study', '38', '11.', 'SAFETY REPORTING', '38', '11.1. Definitions', '38', '11.1.1.', 'Adverse Event (AE)', '38', '11.1.2.', 'Serious Adverse Event (SAE)', '38', '11.2.', 'Reporting Procedures', '38', '11.2.1. Events exempt from being reported as SAEs', '39', '11.3. Death during the study', '39', '11.4. Elective admissions and supportive care', '40', '11.', 'STATISTICS AND ANALYSIS', '40', '11.1. Statistical Analysis Plan (SAP)', '40', '11.2. Description of the Statistical Methods', '40', '11.3. Sample Size Determination for IDEAL IIB Study (Stage 1)', '41', '11.4. Sample Size Determination for the RCT (Stage 2)', '41', '11.5. Recruitment Predictions for the RCT (Stage 2)', '41', '11.6.', 'Analysis populations', '42', '11.7.', 'Decision points', '42', '11.7.1.', 'Stage 1 (IDEAL IIB study)', '42', '11.7.2.', 'Stage 2 (RCT)', '42', '11.8.', 'Stopping rules', '43', '11.8.1.', 'Stage 1 (IDEAL study)', '43', '11.8.2.', 'Stage 2 (RCT)', '43', '11.9. The Level of Statistical Significance', '43', '11.10. Procedure for Accounting for Missing, Unused, and Spurious Data', '43', '11.11. Procedures for Reporting any Deviation(s) from the Original Statistical Plan', '43', '11.12. Health Economics Analysis', '44', '12.', 'DATA MANAGEMENT', '44', '12.1.', 'Source Data', '44', 'Clinical Research Protocol Template version 14.0', 'Page 5 of 65', 'C Copyright: The University of Oxford and Oxford University Hospitals NHS Foundation Trust 2018', 'CONFIDENTIAL']\n\n###\n\n", "completion": "END"}